Listen to article
7:18Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 5 October 2026
Read article
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Let’s be honest, who among us hasn’t stared at a blister pack of pills and thought, there must be a better way? The daily ritual of remembering medication is a universal chore. Forgetting a vitamin is one thing, but for millions managing chronic conditions, a missed dose can have serious consequences. It’s a colossal, expensive problem, and frankly, it’s a bit archaic. I think the pharmaceutical industry has finally woken up to this, and its solution might just be a shot in the arm for investors.
The core issue here isn’t the medicine itself, it’s us. We are forgetful, busy, and inconsistent creatures. Studies show that up to half of all patients with long term conditions don't take their medication as prescribed. This isn't just a minor inconvenience, it leads to poorer health outcomes and costs healthcare systems, like our beloved NHS, an absolute fortune. For years, the industry’s answer was, well, to just make more pills.
Now, a much cleverer approach is gaining serious momentum. Instead of a daily pill, imagine a single injection every month, or even every few months. This whole shift is what some are calling the Injectable Drug Revolution: What's Next Beyond Pills?, and it’s about time. We’re seeing real proof of concept, too. GlaxoSmithKline recently got its long acting HIV prevention jab approved for NHS reimbursement. To me, that’s a massive signal that the powers that be are willing to pay a premium not just for a drug, but for the convenience and compliance that comes with it.
So, who should investors be watching in this space? GSK is clearly a frontrunner. Having navigated the regulatory maze with its HIV treatment, it has a clear head start and a pipeline that suggests this is a long term strategy, not a one off punt. They’ve proven the commercial model works.
Then you have firms like Vertex Pharmaceuticals. They’ve made their name tackling complex rare diseases, which requires some seriously sophisticated science. Their expertise in advanced drug delivery makes them a fascinating player. They might not be the most obvious name in injectables right now, but they have the brains and the technical clout to make a significant impact if they choose to pivot more aggressively in this direction.
And let’s not forget the specialists. A company like Alkermes has built its entire business around this concept, particularly for treating mental health and addiction. These are areas where ensuring a patient stays on their medication is notoriously difficult, giving Alkermes a unique and valuable niche. They’ve been quietly perfecting this technology whilst the giants were focused elsewhere.
The investment case seems rather compelling. These long acting formulations are complex to develop and manufacture, which creates a natural barrier to entry for cheap generic competition. This could mean longer, more profitable patent lives. Furthermore, healthcare providers are desperate for solutions that improve patient outcomes and reduce long term costs, so they may be willing to pay higher prices for these advanced treatments.
Of course, it’s not all smooth sailing. These drugs are expensive to develop, and not every medication can be successfully converted into a long release formula. There’s also the human element. Whilst many might jump at the chance to ditch daily pills, others have a genuine fear of needles. Manufacturing these complex medicines at scale is another significant hurdle. Still, looking at the broader trends in healthcare, from telemedicine to personalised medicine, this move towards less frequent, more manageable treatments feels less like a fad and more like the future.
View the full Basket:Injectable Drug Revolution: What's Next Beyond Pills?
View the full Basket:Injectable Drug Revolution: What's Next Beyond Pills?
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 5 October 2026
Read article
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
